Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

Answer questions and earn CME/CNE Extranodal marginal zone lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma) accounts for 7% to 8% of newly diagnosed lymphomas. Because of its association with infectious causes, such as Helicobacter pylori (HP) or Chlamydophila psittaci (CP), and aut...

Full description

Saved in:
Bibliographic Details
Published in:CA: a cancer journal for clinicians 2016-03, Vol.66 (2), p.152-171
Main Authors: Raderer, Markus, Kiesewetter, Barbara, Ferreri, Andrés J. M.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Antibiotics
antigen‐driven malignancy
Autoimmune Diseases - complications
Chlamydophila psittaci
Disease management
Drug therapy
extranodal
Helicobacter Infections - complications
Helicobacter pylori
Humans
Lymphoma
Lymphoma, B-Cell, Marginal Zone - diagnosis
Lymphoma, B-Cell, Marginal Zone - microbiology
Lymphoma, B-Cell, Marginal Zone - pathology
Lymphoma, B-Cell, Marginal Zone - therapy
Neoplasm Staging
non‐Hodgkin lymphoma
Pathology
Prognosis
Psittacosis - complications
Radiation
Radiotherapy, Adjuvant
Risk Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Answer questions and earn CME/CNE Extranodal marginal zone lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma) accounts for 7% to 8% of newly diagnosed lymphomas. Because of its association with infectious causes, such as Helicobacter pylori (HP) or Chlamydophila psittaci (CP), and autoimmune diseases, it has become the paradigm of an antigen‐driven malignancy. MALT lymphoma usually displays an indolent course, and watch‐and‐wait strategies are justified initially in a certain percentage of patients. In patients with gastric MALT lymphoma or ocular adnexal MALT lymphoma, antibiotic therapy against HP or CP, respectively, is the first‐line management of choice, resulting in lymphoma response rates from 75% to 80% after HP eradication and from 33% to 65% after antibiotic therapy for CP. In patients who have localized disease that is refractory to antibiotics, radiation is widely applied in various centers with excellent local control, whereas systemic therapies are increasingly being applied, at least in Europe, because of the potentially systemic nature of the disease. Therefore, the objective of this review is to briefly summarize the clinicopathologic characteristics of this distinct type of lymphoma along with current data on management strategies. CA Cancer J Clin 2016;66:152–171. © 2015 American Cancer Society.
ISSN:0007-9235
1542-4863
DOI:10.3322/caac.21330